According to Credit Suisse, Suboxone still constitutes about 7 percent of Dr Reddy#39;s Labs#39; base EBITDA, and the entry of Apotex could potentially impact 40 percent of DRL#39;s EBITDA from Suboxone or 3 percent of consolidated EBITDA.

Tags: Previous Next
Generated by Feedzy